Poseida Therapeutics (PSTX) said Monday it is presenting new data analysis of potential allogeneic cell therapy P-BCMA-ALLO1 in patients with relapsed/refractory multiple myeloma as well as new preclinical data supporting P-CD19CD20-ALLO1's anti-cancer profile.
Interim clinical data from its phase 1 trial of P-BCMA-ALLO1 showed a 91% overall response rate in the optimized lymphodepletion arm, with a 100% response in B-cell maturation antigen, or BCMA-naive patients, the clinical-stage biopharmaceutical company said, adding that the therapy showed favorable safety, with "no dose-limiting toxicities" and low rates of side effects.
Poseida said additional profiling of patient responses in the optimized lymphodepletion arm showed consistent P-BCMA-ALLO1 cellular expansion across patient subgroups, with an average manufacturing wait time of only 3.5 weeks.
The company also presented preclinical data for P-CD19CD20-ALLO1, an investigational allogeneic cell therapy for B-cell malignancies and Poseida's first dual CAR-T program, demonstrating "strong" antitumor activity.
Price: 9.45, Change: +0.09, Percent Change: +0.91
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.